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Abstract 
 
Nephrotic syndrome is a term describing a group of poorly understood glomerular diseases that are 
responsible for a steadily increasing number of patients requiring active uremic care. Characteristic 
symptoms of nephrotic syndrome are proteinuria, hypoalbuminemia, hyperlipidemia and peripheral 
edema, and treatment of these symptoms, rather than their cause, is currently the only option 
available to the clinician. While the mechanisms underlying these diseases remain elusive, a 
number of studies have lately revisited adrenocorticotropic hormone (ACTH) as a potential 
treatment option since it has been shown to reduce proteinuria and improve glomerular function. 
Thus, the aim of this thesis has been to elucidate the mechanisms behind this treatment strategy.  
 
The hypothesis is that ACTH mediates its effect by a kidney specific receptor. The gene expression 
of all ACTH receptors, melanocortin receptors (MCR) 1-5, was therefore investigated. MC1R gene 
expression was detected in kidney tissue, including cells specific for the glomerular filtration barrier 
(endothelial cells, podocytes and mesangial cells). MC1R protein was also detected and found to be 
co-localized with synaptopodin, a podocyte specific marker. In order to assess the relevance of 
MC1R in disease, selective agonists were used in experimental nephrotic models. MC1R agonists 
ameliorated the disease in a rat model resembling membranous nephropathy, and reduced 
proteinuria, improved morphology and reduced oxidative stress. MC1R agonists did not reduce 
proteinuria in a model resembling focal segmental glomerulosclerosis, suggesting different 
mechanistic pathways. Signaling pathways were investigated by stimulating podocytes with a 
selective MC1R agonist. Several known intracellular pathways were activated, including cAMP, 
phosphorylation of ERK1/2 and activation of catalase, an anti-oxidative enzyme. MC1R stimulation 
may also have a protective effect in nephrotoxin-induced rearrangement of the actin cytoskeleton. 
 
In conclusion, this thesis has provided new data on the mechanisms behind the beneficial effects of 
ACTH treatment in nephrotic patients. MC1R, expressed in podocytes, likely mediates these 
effects. The results presented herein will pave the way for new, more specific and possibly curative 
treatment options, without severe side effects, for nephrotic patients. 
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